Anyvision Favorability Statistics 2021

By Zach Segal, Published Feb 02, 2021, 09:09am EST (Info+)

Anyvision has raised over $100 million since 2019 as part of its plan to hit $1 billion in sales in 2022. How much has this money helped them gain recognition and a positive reputation?

IPVM Image

Inside this report, we examine the key themes for 200+ integrators favoring and opposing Anyvision.

Favorability *******

***** *********'* ************ *** ******** *** positive *******, **** **** **% ** respondents *** ** ******* ** *********.

IPVM Image

********* *** ******** **** ****-***** ******* of *** *.*. *** *** ******* net *************:

IPVM Image

Key ******

*********** *** **** ***** ********* **** largely ******** ***** *** ******* *** negative ***** *** *****, ********* *******, and ******** ** ****** ** **** response:

**** ********* ****** ***********, **** ****** of **** **** ********. **** *****/***** a ***** ***** ***** *** **** couple ** ***** ** **** ******** but ****'* ********* *** ******. ****** recognition *** ****** **** **** ******** since ** * ***** ***** ***** then **** ********* ******* *** ** market * *** ***** ***.

Most **********'* ******* ** *********

******* ******* ****$*** ************ **** *** ****************** ***/******** ** ***** **% ** respondents *** *** **** *** ********* was:

  • "**** *** **** ****. *** **** known"
  • "*******"
  • "***´* **** *** *****"
  • "*** ******** **** ****"
  • "***'* *** **** ***!"
  • "***** ***** ** **."
  • "***** ***** ** ****"
  • "*** ********"
  • "** **********"
  • '*.*."
  • "**** ***** ***** **** ****."
  • "** **** ***** ***** ** *********.***. With **** ***** ****, ** **** never ******** *** ** ***** *********."
  • "**** ***** ***** ** **"

** ** ****** *** ******** ** have *** **** ***********, ** *** integrator **********, ****** *********'* ******** *** atypically ****.

Sales ******** *** ******* ******* ***-****

******* *********** ******** *** *********’* ***** operated, ******* ** *** *** ** turnover, ** ********* ******/*******.

  • "** **** ** ********* ******* ******* of *** **** ****** ** ******** in ***** ***** *****. ****** *********** in ******* ************** *** ** ******* elsewhere *** *** ***** ***** **/******** needs"
  • "********* ****** *** *********** ***** **** ID *** ******** *******. ******** *** resolution *** ********* ** ******** *******. Most ******** ****** ******** ** *** meet ***** ************."
  • "**** ******** **** ******** ******* **** end *****, *** ***** ******** ******* what **** *** ******** *******"
  • "* *** ** *** ** **** marketing. ***** **** *** ****** ** testing"
  • "*** **********, **** ********** ** *** sale *** *** ** ********** *************"

*********

******* *********** **** ********* **** ********* was *********, ~$*,******** ******* **. **** **** ******* manufacturers.

  • "* **** ****** ** **** ** customers ***** ** *** *** **** vs ******* ****'* *** **** **** budgets"
  • "* **** **** *'** ****, *** the **** ***'* *********** *** *** markets * *****"
  • "********* *** ***** ***** * ******* this ** *** ****"

Positive ******** ***** **********

*********** **** ******* ******** ***** *** technology ******.

  • "** **** *** * *** ** success **** *** ********* ******* ****. For ****** *********** ** ** ** amazing ******* ****. ********* ******** *** the *********** ******** ** *** ***** have * *** ** **** ** do ** ***** **. * ** excited ** *** **** ** ***** new ******* ********* **** **** ***** a ****** **** *** ** * more *********** *****. *** **** ******** we **** *** *** ********* *** been *******. **** ** ** ** place ** ***** ** **** ** body ***** ** **** ***** ** in **** ** ************ *** *** of ****** ***********. ** ** *** of ***** ** *** **** **** you **** ********."
  • "***** ********** *** ***** ********* *** some ******** *******."
  • "**** *** ***** ** *** **** promoting ********* ** ***** ** ****** is **** ****. ******* ***** ******** there *** **** ***** ******** ****** since **** **** ******* ** ********** people *** ** *** ** ******* the ********. ******* *** **** *** very **** ******* *******, ** ****** how **** *** ****** **** ******* is **** *********"
  • "***** ********* *** ****** ***********. **** need ****** *** ******"
  • "***** **********"

Face *********** *************

********* ***** **** *********** ***** ** controversial *** ***** ******* **********, ********** in *** *.*. *** *.*. ******* integrators ********* ********** ******* ** *** technology **** ****. ** ********, *********** has *** ****** ****** ** **** *********** ********** **** ** ******. *********’***** ****** ******* ******* $** ******* *** ** ***** money ** ********** **** ************ ** access ******* *** **************.

  • "* ** *** * *** ** facial ***********.
  • "'** ********* ********* ******** ****** **** identifies ******* ** ******** *** ***** contact ******* ** ****-**** *** ************ while ********** *** ******** ** **********.' No ******"
  • "***** ********** ** ********** *** ****** well ** * **** ** *** on * ******** ****. *** ***** is **** ****** **** *** ****** recognition *** ***** ****** **** *************. There ***** ** ** ***** * bit ** ******** ** ****"
  • "***** ***** ** ******* ******* ********** is ** *********** ******* *** ***** skeptical ** ** *** **** **** fit ** **** **** ************"

A *** ** ***** ***** **** ***** *******

***** ******** **** ***** ********* ****** over$** ******* ** **** **** ******* ************ ************ ****-*********** ********. ******** ********* ********** ******* *******$** ******* **************** *** ** ***********. ***** ** negative ******** ***** ********* ***** ******* and ********, ***** **** ****** **% of *********** ********* “***’* ****”, ***** aggressive (*** *********) ******* **** *** delivered * ******. *******, **** ******** a *** ******** ****** ******* ******* a ************* ********** *** *********** **** largely ******** ***** *** ******* ** their **** *********** **********.

Comments (15)

***** *******. *****.

Agree
Disagree
Informative
Unhelpful
Funny

**** ********* * **** ****, *** way **********.

Agree
Disagree
Informative
Unhelpful
Funny

* *** ******** **** ** ******** and ******* ******* **** ********* ******* and ******* *** *** ***** ** wanted ** ** ** ** ***** of ********. *** ** *** ***** and *** ****** ** ******** **** very **** ** **** ** *** you **** **** *** *********... ***** makes ** **** *********.

Agree
Disagree
Informative
Unhelpful
Funny

"******* *********** **** ********* **** ********* was *********, ~$*,*** **** * ******* vs. **** **** ******* *************." ***'* offering *** ****? * ***** **** Herta ****** *** ***** *** **** price ** *********. ** ***** ** indeed * **** ***** ******* ****** the ********** ****** **** ** **** in ***** ********* ******** ***** ***** scales **** *** ***** *** *******.

Agree
Disagree
Informative
Unhelpful
Funny

***'* ******** *** ****?

*****, *********, ***, ***.

** ******, *** ***** ** ******* and *********** ** *****. *** ***** is **** ******** *****, ****** *****, which ***** *********, *****, ***. *** other ***** ** **** ******** * years **** ***, ***** **** ****** to *******, ***** ** * **** for *********, *****, ***.

Agree
Disagree
Informative
Unhelpful
Funny: 1

******* ******* **** ***** *** ********* are ******** ******* ****** **** ********* in *** **** ****** *********** ******** tests, *** * ******* **'* * different ****** ***** ***** ********* *** sanctioned ** *** ** ********** *** human ****** ******. * ***** ******* sane ** *** ***/** ***** *** a ********* ******** ****** ******** ********* PII **** ****, ****** *** ******** is **** ** ***** **********, ********* even ******* **** **** ** **** a ******!

Agree
Disagree
Informative
Unhelpful
Funny

******* ******* **** ***** *** ********* are ******** ******* ****** **** ********* in *** **** ****** *********** ******** tests

****'* **********. **** **** *** **** commercial ********. **** **** **********.

*** **** *********** **** ***** *** Hikvision **** **** *** **** ** far, *** ******** ** ********* *** Herta. ******* ***** *** ********* ******** have ***** ****** *********** ** ***** or **** ***** **** **** ******** works *** ****** **** ********* ** Herta, ** ****** ***. *** *** actual ********** ******* ********** ** * different *****, **** **** **** *****?

Agree
Disagree
Informative
Unhelpful
Funny

****'* **********. **** **** *** **** commercial ********. **** **** **********.

** *** *** **** **** ***'* NIST ******* **. ****-***** *********** ** the **.

** ******* *********** ************* *******, **** ****:

***-*, ** ** **** ********, *** most ******** ** **** *********.

***, ** ****, ** **** ********** by ** ******,* *** ********* (***)******** */**** ** *** **** ** raised ** *****.

Agree
Disagree
Informative: 1
Unhelpful
Funny

*** **** *** **. *** ** can't ********* *** ************ ** *** to *** *********** ** *** ********** market *******

Agree
Disagree
Informative
Unhelpful
Funny

* **** **** *** *****, ********* engines **** ** **********. **** ** good ** ***** *****. *** ******* problem *** ******* ******* ** **** their ******* ** ******* ** *** multi-race ************. **** ******* ****** ***** that **** **** ******* ***** ***** (including *** **** ****** **** ** NIST ****).

*** *** ******* **** **** ** the ******* **** *** ******** ** NIST **** ***'* **** *** **** level ** *********** ** ***** ************ available ********.

Agree
Disagree
Informative
Unhelpful
Funny

***** ******* *****. *** ********* ******* inside *** ****** *** **** ** the ******* ****** *** *** ** exactly *** **** ** ****'* ****** by ****, *** *** ***** ** what *** ******* ****** ** *** be ********* **** **** *** ******* vendors **** ** **** ** ***** of ***, *** *** ***** ************ etc. *******, * ***** *** ** as *** ** ******* *** ******* products *********** ******** - **** ** us ******* *** ***** **** *** claim *********** ** *** ***** ** Uygur ********** ************, ********* ** ***** streams! *** *** ******* **, ** seems ** ** ******* ** **********...

Agree
Disagree
Informative
Unhelpful
Funny

*******, * ***** *** ** ** far ** ******* *** ******* ******** technically ********

**'** ****** ***** ********, **** *** inferior. ** ******, ******* ***** *** Hikvision **** ***** ******** ******** **** only **** ** *****. ****'* * possibility, ****** * ** *********.

*** ***** ** ***** ********** ************, thousands ** ***** *******! *** *** problem **, ** ***** ** ** working ** **********...

**** ******** ** *** **** ** that? * **** **** ** ******** that **** **** ** ********* *** I *** **** *** **** **** of *** *******'* *** *************** **** told ** **** ***'* **** ****, i.e., ********** (************ ****** ***********).

Agree
Disagree
Informative
Unhelpful
Funny

****** ***** ****'* **** **** **** effectiveness ***** **** ***** ** *** level **** **** ***** **** **********. However, *** ********* ******** ** ***** convincing, ** * ****** ** ******** like *********’* **** ************ ******* **** **** 7 ******* ** ******* *** ******** **********. *********, *********** ** * ****** is ****** ***** ** ********* ********** and ****** (**** **** ****** ** use ** ** ********* ********* ***** affiliation, *** ***********, ******** ****, **, etc.), *** ******** * ******** ****** on * ********* ** ******* **** those ******* *** ** **!

Agree
Disagree
Informative
Unhelpful
Funny

*******, *** ********* ******** ** ***** convincing, ** * ****** ** ******** like **** *****’* **** ************ ******* took **** * ******* ** ******* BBC ******** – **********.

****'* ****** ********. ********* **** **** ** **** **** it ********, *** ******:

*** *** ******** *** *** **** added ** *** ******, ** **** goes ** * ******-******* ********** *** the ****** ******* ***. **** ******* the **** ***** ***** ** *** report, **** *** ****** *** *** in **** * *******:

IPVM Image

**** ** ********. *** *-****** ***** spooked ****** ******* *** ****** *** boosted **********. *** *** ******* ** that **** ** * ******** ** a ****** ***** ******* * ******-******* checkpoint, ***** ****** *** *****. ** would ** *** ****** ** ***** them ** ***** **** ** ******* down *** ******. **** ** ********* the ********/***** ** *** ***, *** not *****, *** ******** ** ********* such * ********.

Agree
Disagree
Informative
Unhelpful
Funny

*** **** *** *******! ******* *** trick **** ** *** ******* ** surveillance ****** ** ******* ***** ******** for * ********* ****** ******** ******* perfectly **** **** **** **** *** would ******* ****** *********, **** ** like *** ***** ******** ****** **** the *******. *** *** ******** ************ ****** *********** ********** ****** ******* ****** **** ********* ********* *** fully ********* - ***** ** ******** a ***** ** *** ***** **** of *** **** *** **** *************, which ** ** ****** *** ********** given *** **** **** ** ********* of ********* **** *** **.

Agree
Disagree
Informative
Unhelpful
Funny
Login to read this IPVM report.
Why do I need to log in?
IPVM conducts reporting, tutorials and software funded by subscriber's payments enabling us to offer the most independent, accurate and in-depth information.
Loading Related Reports